Skip to main content
Signal8
Launch Terminal

Nkarta, Inc. (NKTX)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Nkarta, Inc. logo

Nkarta, Inc.

NASDAQ:NKTXHealthcare
-6.02%$1.56
AH$1.60+2.56%vs close
Mkt Cap$111.73M
Float49.98M
O/S71.62M
Vol
$ Vol
RVOL
Inst Own82.9%
SI6.8%
Earnings
Dilution
Nkarta, Inc. logoNASDAQ:NKTX$1.56-6.02%
Pipeline4 lead-sponsored trials·4 active0 completed(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 1/2
    Recruiting

    A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

    NKX019, Fludarabine, Cyclophosphamide

    Lupus Nephritis, Primary Membranous Nephropathy

    Enrollment
    120
    Start
    Jun 2024
    Primary Completion
    Apr 2027est.
    Completion
    Apr 2027est.
    NCT06557265
  • Phase 1/2
    Recruiting

    A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

    NKX019, Fludarabine

    Systemic Sclerosis, Idiopathic Inflammatory Myopathies +2

    Enrollment
    240
    Start
    Nov 2024
    Primary Completion
    Oct 2028est.
    Completion
    Oct 2028est.
    NCT06733935
  • Phase 1
    Active, not recruiting

    NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

    NKX101 - CAR NK cell therapy

    Relapsed/Refractory AML, AML, Adult +2

    Enrollment
    61
    Start
    Sep 2020
    Primary Completion
    Oct 2024
    Completion
    Jul 2039est.
    NCT04623944
  • Phase 1
    Active, not recruiting

    NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

    NKX019

    Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia +8

    Enrollment
    150
    Start
    Aug 2021
    Primary Completion
    Mar 2025
    Completion
    Dec 2038est.
    NCT05020678
Search ClinicalTrials.gov for “Nkarta”